Compare Campbell Soup Co. (CPB) vs 10X Genomics Inc (TXG) Price & Performance

Campbell's (CPB) trades at $22.15, up 0.36% with neutral technical signals. The stock shows modest valuation metrics with P/E of 10.85 and P/S of 0.67, while recent earnings show mixed results with Q1 2026 beating expectations. Revenue growth remains stable at $10.25B for 2025, though profit margins have compressed from historical levels. The company maintains strong cash flow generation and recently launched new product innovations including protein soups and gluten-free options.

CPB offers value investors an attractive 7% dividend yield and reasonable valuation, but faces margin pressure and competitive headwinds. Analyst consensus leans cautious with 58.6% hold ratings, though recent product launches and cost initiatives provide potential catalysts. Key risks include ongoing margin compression and consumer spending sensitivity in the current economic environment.

TXG trades at $41.77, down 2.25% today, with a bullish technical setup supported by moving averages. The company shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while recent collaborations with Cleveland Clinic and the Proteintech acquisition expand its diagnostic capabilities. Analyst sentiment is mixed with 45% buy ratings but a consensus price target below current levels.

The outlook suggests cautious optimism as TXG demonstrates operational improvement with positive cash flow generation, though profitability remains elusive. Key risks include execution challenges in new ventures and competitive pressures, while upside potential hinges on continued margin expansion and successful integration of recent acquisitions.